within Pharmacolibrary.Drugs.ATC.L;

model L04AA04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.5e-08,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 7.000000000000001e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0001,
    k12             = 0.01,
    k21             = 0.01
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Antithymocyte immunoglobulin (rabbit) is a purified, polyclonal IgG preparation derived from rabbits immunized with human thymocytes. It is used as an immunosuppressive agent primarily to prevent and treat acute rejection in organ transplantation, particularly kidney transplantation, and is also utilized in the treatment of aplastic anemia. It is an approved drug widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult kidney transplant recipients receiving antithymocyte immunoglobulin (rabbit); typical IV dose 1.5 mg/kg daily for 4 to 7 days, administered via intravenous infusion.</p><h4>References</h4><ol><li><p>McCune, JS, et al., &amp; O&#x27;Donnell, PV (2012). A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. <i>Cancer chemotherapy and pharmacology</i> 69(1) 263–272. DOI:<a href=\"https://doi.org/10.1007/s00280-011-1736-3\">10.1007/s00280-011-1736-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21909959/\">https://pubmed.ncbi.nlm.nih.gov/21909959</a></p></li><li><p>Russell, JA, et al., &amp; Daly, A (2013). Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. <i>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</i> 19(9) 1381–1386. DOI:<a href=\"https://doi.org/10.1016/j.bbmt.2013.07.002\">10.1016/j.bbmt.2013.07.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23871781/\">https://pubmed.ncbi.nlm.nih.gov/23871781</a></p></li><li><p>Andersson, BS, et al., &amp; Champlin, RE (2011). Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. <i>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</i> 17(6) 893–900. DOI:<a href=\"https://doi.org/10.1016/j.bbmt.2010.09.022\">10.1016/j.bbmt.2010.09.022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20946966/\">https://pubmed.ncbi.nlm.nih.gov/20946966</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AA04;
